The HIV epidemic has been met with an unprecedented international response including financing for prevention and treatment interventions. For the money to be spent efficiently robust estimates for the balance between effectiveness and costs are needed. To support this need the WHO has published cost-effectiveness analysis guidelines for the evaluation of HIV prevention interventions. Our CFAR Health Economics Impact Study Team will provide researchers with the tools to evaluate the costs and cost-effectiveness of HIV/AIDS prevention and treatment interventions; providing information for decision makers to define priorities and allocate resources. A team has been assembled, included academics and experts in development.
The areas of expertise of the team include health economics, mathematical modeling, epidemiology, clinical trials, infectious diseases and health metrics. The Study Team includes representatives from the University of Washington; the Bill & Melinda Gates Foundation; University of California, San Francisco; and University of California, Berkeley as well as from the CFAR Sociobehavioral & Prevention Research Core and Implementation Science Working Group.
Our goal is that incorporation of health economic evaluations will become the rule rather than the exception in study development.
Resources from Past Workshops:
- Costing Series, Part 2, February 9, 2017
- Costing Series, Part 1, October 13, 2016.
- Seattle, WA: May 2015, April 2016
- Kisumu, Kenya